Pharmaceutical

Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site

Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of…

2 months ago

Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the…

2 months ago

CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Celebrates 50 Years of Global Pharmaceutical Excellence

This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwideWATFORD, United Kingdom and BERWYN, Pa.,…

2 months ago

Immuron Q1 FY26 YoY growth

Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on…

2 months ago

ITM Appoints Annette Breunig as Chief People Officer

ITM Announcement Headshot CPO Annette Breunig Annette Breunig, Chief People Officer of ITM Global HR leader to drive ITM’s long-term…

2 months ago

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30…

2 months ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapiesHONG…

2 months ago

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO…

2 months ago

EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm

DUBAI, United Arab Emirates, Oct. 12, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, a global pharmaceutical services and life sciences solutions…

2 months ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…

2 months ago